Esperion Therapeutics, Inc. 8-K

What Happened

• Esperion Therapeutics, Inc. announced that its stockholders approved the Agreement and Plan of Merger dated May 1, 2026, among Esperion, Essence Parent Inc. (Parent) and Essence MergerCo Inc. At closing, MergerCo will merge with and into Esperion, with Esperion surviving as a wholly owned subsidiary of Parent, subject to the conditions in the Merger Agreement. The approval did not include the debt-financing or any Parent co‑investment.

Key Details

• Record date and meeting turnout: 257,693,347 shares outstanding as of May 28, 2026; 158,573,615 shares (61.53%) were represented at the July 8, 2026 special meeting (quorum).
• Merger vote: 135,326,793 votes FOR, 22,750,628 AGAINST, 496,194 ABSTENTIONS, 0 broker non-votes.
• Advisory (non‑binding) executive compensation vote: 129,937,383 FOR, 22,283,787 AGAINST, 6,352,445 ABSTENTIONS.
• The filing reiterates forward‑looking statement cautions and notes contingent payments under any CVR (contingent value rights) depend on future net‑sales milestones.

Why It Matters

• The stockholder approval is a major step toward Esperion becoming a wholly owned subsidiary of Essence Parent, but the transaction remains subject to closing conditions (including financing and other conditions in the Merger Agreement). Investors should note the merger approval does not guarantee closing and that CVR payments (if any) depend on future commercial performance. The advisory vote on compensation was approved but is non‑binding.